Recent Company News

• 09:04 AM ET Oct 02, 2026
  

  Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting ($3.18, 0.00)

• 07:31 AM ET Aug 20, 2026
  

  Evaxion AS reports Q2 EPS ($0.01) vs year-ago ($0.02) ($3.15, 0.00)

• 07:29 AM ET Aug 20, 2026
  

  Evaxion announces business update and second quarter 2026 financial results

• 08:04 AM ET Aug 17, 2026
  

  Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program ($3.34, 0.00)

• 10:59 AM ET Jul 12, 2026
  

  Evaxion AS presents new preclinical data on EVX-V1 at IHW 2026 ($3.17, 0.00)

• 02:15 AM ET Jun 11, 2026
  

  Evaxion AS to present new preclinical data for EVX-04 at EHA 2026 Congress ($3.79, 0.00)

• 07:43 AM ET May 07, 2026
  

  Evaxion AS reports Q1 EPS ($0.01) vs FactSet ($0.01) [1 est] ($4.41, 0.00)

• 03:13 PM ET Apr 17, 2026
  

  Evaxion's AI-Immunology platform demonstrates 86% vaccine target precision in Phase 2 personalized cancer vaccine trial ($4.39, +0.25)

• 03:04 PM ET Apr 17, 2026
  

  Evaxion AS announces presentation of new data on its AI-Immunology platform in glioblastoma ($4.45, +0.31)

• 08:06 AM ET Apr 07, 2026
  

  Evaxion announces last patient visit in one-year extension of phase 2 trial with personalized cancer vaccine EVX-01 ($3.73, 0.00)